Postmenopausal Osteoporosis
126
4
7
98
Key Insights
Highlights
Success Rate
99% trial completion (above average)
Published Results
45 trials with published results (36%)
Research Maturity
98 completed trials (78% of total)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
0.8%
1 terminated out of 126 trials
99.0%
+12.4% vs benchmark
48%
61 trials in Phase 3/4
46%
45 of 98 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 98 completed trials
Clinical Trials (126)
Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis Risk in Postmenopausal Females
Dried Plums and Bone Health in Postmenopausal Women
Progressive Strength and Balance Exercise for Fall Prevention in Postmenopausal Women With Osteoporosis
Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis
Can Serum Lumican Level Identify a Hidden Fragility Phenotype Beyond Bone Mineral Density in Postmenopausal Women?
Anabolic Therapy in Postmenopausal Osteoporosis
The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation
A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)
A Phase 3 Study to Compare Biosimilar Denosumab With Prolia®
AGE Burden and Response to Antiresorptive Therapy in Osteoporosis
StrAtegies For Zoledronic Acid Post-dEnosumab Discontinuation in Postmenopausal oSTeoporosis
A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.
Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women
Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis and CVD Risk
A Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Immunogenicity of FKS518 in Postmenopausal Women With Osteoporosis
Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® .
A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis
Alendronate in an Weekly Effervescent Tablet Formulation Following Denosumab Discontinuation
Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis